EP1417304A4 - Methode et composition permettant d'inhiber l'activite de l'heparanase - Google Patents

Methode et composition permettant d'inhiber l'activite de l'heparanase

Info

Publication number
EP1417304A4
EP1417304A4 EP02763248A EP02763248A EP1417304A4 EP 1417304 A4 EP1417304 A4 EP 1417304A4 EP 02763248 A EP02763248 A EP 02763248A EP 02763248 A EP02763248 A EP 02763248A EP 1417304 A4 EP1417304 A4 EP 1417304A4
Authority
EP
European Patent Office
Prior art keywords
immunogen
heparanase
composition
present
heparanase activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02763248A
Other languages
German (de)
English (en)
Other versions
EP1417304A2 (fr
Inventor
Peter Bohlen
Daniel Hicklin
Paul Kussie
Yiwen Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
ImClone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImClone Systems Inc filed Critical ImClone Systems Inc
Publication of EP1417304A2 publication Critical patent/EP1417304A2/fr
Publication of EP1417304A4 publication Critical patent/EP1417304A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01166—Heparanase (3.2.1.166)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)

Abstract

L'invention concerne des méthodes permettant d'inhiber l'activité de l'héparanase et de traiter différents états par administration, à un animal, d'une quantité efficace d'un immunogène sollicitant une réponse immunitaire contre l'héparanase. Selon l'invention, l'immunogène est l'héparanase ou un fragment de celle-ci, cet immunogène étant, de préférence, une cellule présentant un antigène (APC), telle qu'une cellule dendritique (DC) affichant l'héparanase ou un fragment de celle-ci sur sa surface. L'invention concerne également des compositions contenant ledit immunogène.
EP02763248A 2001-07-13 2002-07-10 Methode et composition permettant d'inhiber l'activite de l'heparanase Withdrawn EP1417304A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30544601P 2001-07-13 2001-07-13
US305446P 2001-07-13
US35755302P 2002-02-15 2002-02-15
US357553P 2002-02-15
PCT/US2002/021773 WO2003006645A2 (fr) 2001-07-13 2002-07-10 Methode et composition permettant d'inhiber l'activite de l'heparanase

Publications (2)

Publication Number Publication Date
EP1417304A2 EP1417304A2 (fr) 2004-05-12
EP1417304A4 true EP1417304A4 (fr) 2005-11-23

Family

ID=26974593

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02763248A Withdrawn EP1417304A4 (fr) 2001-07-13 2002-07-10 Methode et composition permettant d'inhiber l'activite de l'heparanase

Country Status (4)

Country Link
EP (1) EP1417304A4 (fr)
JP (1) JP2005521379A (fr)
CA (1) CA2453566A1 (fr)
WO (1) WO2003006645A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1479764A1 (fr) * 2003-05-19 2004-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Peptides derives de Heparanas pour la vaccination des patients cancereux
ES2251289B1 (es) * 2004-02-27 2007-07-01 Bioiberica, S.A. Nuevo uso terapeutico de un grupo de polisacaridos sulfatados.
JP5722030B2 (ja) * 2008-03-31 2015-05-20 株式会社 資生堂 しわを防止または改善するための経口、注射、皮膚外用剤および美容方法
WO2016036782A1 (fr) * 2014-09-02 2016-03-10 The Children's Hospital Of Philadelphia Compositions et procédés permettant l'inhibition de la chondrogenèse

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011798A1 (fr) * 1997-09-02 1999-03-11 Insight Strategy & Marketing Ltd. Polynucleotide codant pour un polypeptide presentant une activite d'heparanase et son expression par des cellules transductees
WO1999057153A1 (fr) * 1998-05-01 1999-11-11 Insight Strategy & Marketing Ltd. Sondes moleculaires specifiques pour heparanase et leur mise en application dans la medecine et dans la recherche
WO2000052178A1 (fr) * 1999-03-01 2000-09-08 Insight Strategy & Marketing Ltd. Polynucleotide codant pour un polypeptide ayant une activite d'heparanase et expression de ce polynucleotide dans des cellules genetiquement modifiees
WO2001035967A1 (fr) * 1999-11-19 2001-05-25 Abbott Gmbh & Co. Kg Inhibiteurs d'heparanase utilises dans le traitement de l'insuffisance cardiaque

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2307830A1 (fr) * 1997-10-28 1999-05-06 The Australian National University Molecule isolee d'acide nucleique codant une endoglucuronidase mammalienne et ses applications

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011798A1 (fr) * 1997-09-02 1999-03-11 Insight Strategy & Marketing Ltd. Polynucleotide codant pour un polypeptide presentant une activite d'heparanase et son expression par des cellules transductees
WO1999057153A1 (fr) * 1998-05-01 1999-11-11 Insight Strategy & Marketing Ltd. Sondes moleculaires specifiques pour heparanase et leur mise en application dans la medecine et dans la recherche
WO2000052178A1 (fr) * 1999-03-01 2000-09-08 Insight Strategy & Marketing Ltd. Polynucleotide codant pour un polypeptide ayant une activite d'heparanase et expression de ce polynucleotide dans des cellules genetiquement modifiees
WO2001035967A1 (fr) * 1999-11-19 2001-05-25 Abbott Gmbh & Co. Kg Inhibiteurs d'heparanase utilises dans le traitement de l'insuffisance cardiaque

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DEMPSEY L A ET AL: "Heparanase, a potential regulator of cell-matrix interactions", TIBS TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER PUBLICATION, CAMBRIDGE, EN, vol. 25, no. 8, 1 August 2000 (2000-08-01), pages 349 - 351, XP004215172, ISSN: 0968-0004 *
DONG JIAN ET AL: "Molecular cloning, chromosomal localization, and expression of mouse heparanase", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 42, March 2001 (2001-03-01), & 92ND ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; NEW ORLEANS, LA, USA; MARCH 24-28, 2001, pages 513 - 514, XP001204179, ISSN: 0197-016X *
LI JIN ET AL: "Immunochemical localization of heparanase in mouse and human melanomas", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 45, no. 6, 15 June 1990 (1990-06-15), pages 1088 - 1095, XP002115495, ISSN: 0020-7136 *
LIDER O ET AL: "Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 20, no. 3, March 1990 (1990-03-01), pages 493 - 499, XP002094004, ISSN: 0014-2980 *
MIAO HUA-QUAN ET AL: "Cloning, expression, and purification of mouse heparanase", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 43, March 2002 (2002-03-01), & 93RD ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; SAN FRANCISCO, CALIFORNIA, USA; APRIL 06-10, 2002, pages 535 - 536, XP001204251, ISSN: 0197-016X *
MIAO HUA-QUAN ET AL: "Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides", INTERNATIONAL JOURNAL OF CANCER, vol. 83, no. 3, 29 October 1999 (1999-10-29), pages 424 - 431, XP009041034, ISSN: 0020-7136 *
PARISH C R ET AL: "TREATMENT OF CENTRAL NERVOUS SYSTEM INFLAMMATION WITH INHIBITORS OFBASEMENT MEMBRANE DEGRADATION", IMMUNOLOGY AND CELL BIOLOGY, CARLTON, AU, vol. 76, 1998, pages 104 - 113, XP002922989 *
THURNER B ET AL: "Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 223, no. 1, 1 February 1999 (1999-02-01), pages 1 - 15, XP004155750, ISSN: 0022-1759 *

Also Published As

Publication number Publication date
WO2003006645A3 (fr) 2003-07-24
EP1417304A2 (fr) 2004-05-12
JP2005521379A (ja) 2005-07-21
WO2003006645A2 (fr) 2003-01-23
CA2453566A1 (fr) 2003-01-23

Similar Documents

Publication Publication Date Title
IN2006KO01346A (fr)
PL331802A1 (en) Substituted cyclic amines as metaloprotease inhibitors
DE69936102D1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
CA2437844A1 (fr) Procede visant a accroitre les taux de leptine a l'aide de composes d'acide nicotinique
WO2005016962A3 (fr) Compositions et techniques de traitement de maladies liees a l'immunite
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
HK1074573A1 (en) Tetrahydroquinoline analogues as muscarinic agonists
TWI265929B (en) Triazinyl derivatives for inhibiting the production of IL-12
WO2000077206A3 (fr) Promoteur du gene de la myostatine et methode pouvant inhiber l'activation dudit promoteur
AU2251901A (en) Methods and compounds for inhibiting MRP1
WO2004043456A8 (fr) Inhibiteurs d'absorption du cholesterol pour le traitement de la demyelination
MXPA01003501A (es) Metodo para moderar el estres o tension de las plantas.
WO2000000198A8 (fr) Derives de piperidine agissant sur les systemes lies a la serotonine
AU9624198A (en) Quinoline and quinazoline derivatives having corticotropin releasing factor (crf) antagonist activity
ES8609312A1 (es) Procedimiento para la preparacion de silibinina exenta de isosilibina
WO2002096420A3 (fr) Procede de traitement d'accidents nerveux entraines par une operation
WO2004032908A3 (fr) Methode d'inhibition de l'angiogenese
WO1993015112A3 (fr) COMPOSES ET PROCEDES D'INHIBITION DE LA FONCTION DE LA PROTEINE $g(b)
WO2003006645A3 (fr) Methode et composition permettant d'inhiber l'activite de l'heparanase
IL165220A0 (en) Novel compounds, their use and preparation
WO2000057908A3 (fr) Vaccin antiviral attenue du dengue de type 1
MXPA03008801A (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.
WO1999057278A3 (fr) Immunisation et traitement anti-infectieux

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040213

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20051006

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060201